BLEPHAMIDE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for BLEPHAMIDE (BLEPHAMIDE).
Combination of sulfacetamide, a sulfonamide antibiotic that inhibits bacterial dihydropteroate synthase, and prednisolone, a corticosteroid that suppresses inflammation by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis.
| Metabolism | Sulfacetamide: hepatic acetylation (N-acetyltransferase). Prednisolone: hepatic metabolism via 11β-hydroxysteroid dehydrogenase and CYP3A4. |
| Excretion | Renal (primarily unchanged drug for sulfacetamide; prednisolone metabolites also renally eliminated). Sulfacetamide: 85-90% excreted unchanged in urine; biliary/fecal <10%. Prednisolone: metabolites excreted renally (~60%) and biliary (~40%). |
| Half-life | Sulfacetamide: terminal half-life 7-13 hours in normal renal function, prolonged in renal impairment. Prednisolone: terminal half-life 2-3 hours. Clinical context: Sulfacetamide's half-life supports twice-daily dosing; prednisolone's short half-life minimizes systemic accumulation. |
| Protein binding | Sulfacetamide: 10-20% bound to plasma proteins (primarily albumin). Prednisolone: 70-90% bound to corticosteroid-binding globulin and albumin. |
| Volume of Distribution | Sulfacetamide: Vd ~0.3 L/kg (limited tissue distribution, remains largely in extracellular fluid). Prednisolone: Vd ~0.6-0.7 L/kg (distributes widely into tissues). Clinical meaning: Prednisolone's larger Vd suggests extensive tissue penetration; sulfacetamide's smaller Vd reflects minimal distribution. |
| Bioavailability | Topical ophthalmic: Systemic bioavailability low (<10% for both components due to limited ocular absorption and nasolacrimal drainage). |
| Onset of Action | Topical ophthalmic: Sulfacetamide onset 1-2 hours for bacteriostatic effect; prednisolone onset 1-2 hours for anti-inflammatory effect. |
| Duration of Action | Topical ophthalmic: Sulfacetamide up to 6-8 hours; prednisolone up to 4-6 hours. Clinical notes: Frequent dosing (every 4-6 hours) required for sustained effect. |
| Molecular Weight | Sulfacetamide: 214.24 Da; Prednisolone: 360.44 Da |
1-2 drops into conjunctival sac every 4-6 hours; in severe cases, every 1-2 hours until improvement, then reduce frequency.
| Dosage form | SUSPENSION |
| Renal impairment | No specific dose adjustment recommended; use with caution in severe renal impairment due to potential systemic absorption of sulfonamide. |
| Liver impairment | No specific dose adjustment recommended; use with caution in severe hepatic impairment due to potential systemic absorption of sulfonamide. |
| Pediatric use | Children ≥2 years: 1 drop into conjunctival sac every 4-6 hours; not recommended for children <2 years due to risk of sulfonamide toxicity. |
| Geriatric use | No specific dose adjustment; use lowest effective dose and monitor for adverse effects due to potential age-related decrease in renal function. |
| 1st trimester | Avoid during first trimester due to potential teratogenic effects of sulfonamides (sulfacetamide) and corticosteroids (prednisolone). Sulfonamides may cause kernicterus in neonates; corticosteroids may increase risk of cleft palate. Use only if clearly needed. |
| 2nd trimester | Use with caution. Potential risks from sulfonamide (kernicterus) and corticosteroid (fetal growth restriction) exposure. Consider alternative therapy if possible. |
| 3rd trimester | Avoid near term due to risk of kernicterus from sulfonamide and potential adrenal suppression in neonate from corticosteroid. Use only if benefit outweighs risk. |
Clinical note
Comprehensive clinical and safety monograph for BLEPHAMIDE (BLEPHAMIDE).
| Placental transfer | Both sulfacetamide and prednisolone cross the placenta. Sulfacetamide crosses readily and may reach fetal serum levels 50-90% of maternal levels. Prednisolone is partially metabolized by placental 11β-HSD2, but significant transfer occurs especially at higher doses. |
| Breastfeeding |
■ FDA Black Box Warning
None
| Serious Effects |
Hypersensitivity to sulfonamides, corticosteroids, or any componentViral infections of the cornea (e.g., herpes simplex keratitis)Fungal infections of the eyeMycobacterial eye infectionsAfter uncomplicated removal of a foreign body from the cornea
| Precautions | Prolonged use may lead to ocular hypertension/glaucoma, Cataract formation, Secondary ocular infections (fungal, viral), Sulfonamide hypersensitivity reactions, Corneal thinning, Delayed wound healing, Systemic absorption effects |
| Food/Dietary | No clinically significant food interactions. No dietary restrictions. |
| Clinical Pearls |
Loading safety data…
| Sulfacetamide may be excreted in breast milk in small amounts; risk of kernicterus in nursing infants is low but caution is advised. Prednisolone is excreted in breast milk in low doses; however, high maternal doses could potentially affect infant adrenal function. Monitor infant for signs of adrenal suppression or jaundice. Use only if clearly needed. |
| Lactation Rating | L3 - Moderately Safe |
| Teratogenic Risk | Pregnancy Category C. Sulfacetamide crosses placenta; risk of kernicterus in third trimester if maternal sulfonamide levels near term. Prednisolone associated with orofacial clefts (first trimester), fetal adrenal suppression (chronic use). Avoid first and third trimesters unless benefit exceeds risk. |
| Fetal Monitoring | Maternal: monitor for hypersensitivity, adrenal suppression, infection. Fetal: growth ultrasound if prolonged use; neonatal monitoring for jaundice, adrenal insufficiency if used near term. |
| Fertility Effects | No known adverse effects on human fertility. Corticosteroids may alter menstrual cycle at high systemic doses; topical ocular absorption is minimal. |
| BLEPHAMIDE (sulfacetamide sodium/prednisolone acetate) is an ophthalmic suspension. Shake well before use. Do not use with soft contact lenses (preservative may discolor). Monitor intraocular pressure (IOP) with prolonged corticosteroid use. Avoid abrupt discontinuation of steroid component. Contraindicated in epithelial herpes simplex keratitis, fungal infections, and sulfonamide hypersensitivity. |
| Patient Advice | Shake the bottle vigorously before each use. · Do not touch the dropper tip to any surface to avoid contamination. · Remove contact lenses before instillation; wait at least 15 minutes before reinserting. · Use exactly as prescribed; do not stop without consulting your doctor. · Report any eye pain, vision changes, or signs of infection (e.g., redness, discharge). · May cause temporary blurred vision; avoid driving until vision clears. |